Cargando…

Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial

BACKGROUND: Perioperative bleeding during total knee arthroplasty (TKA) is an ongoing problem for surgeons. Intravenous or topical application of tranexamic acid (TXA) can effectively stop bleeding, but there is still no uniform standard for the best method of administration and dose. METHODS: From...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shenqi, Wang, Chengbin, Shi, Lei, Xue, Qingyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709093/
https://www.ncbi.nlm.nih.gov/pubmed/31348286
http://dx.doi.org/10.1097/MD.0000000000016570
_version_ 1783446129284743168
author Zhang, Shenqi
Wang, Chengbin
Shi, Lei
Xue, Qingyun
author_facet Zhang, Shenqi
Wang, Chengbin
Shi, Lei
Xue, Qingyun
author_sort Zhang, Shenqi
collection PubMed
description BACKGROUND: Perioperative bleeding during total knee arthroplasty (TKA) is an ongoing problem for surgeons. Intravenous or topical application of tranexamic acid (TXA) can effectively stop bleeding, but there is still no uniform standard for the best method of administration and dose. METHODS: From October 2016 to September 2018, 218 patients with unilateral primary knee osteoarthritis requiring knee replacement were enrolled and randomly divided into four groups. Group 1 (n = 55) received intra-articular injection (IAI) of TXA and peri-articular injection (PAI) of placebo, group 2 (n = 55) received IAI of placebo and PAI of TXA, group 3 (n = 51) received IAI of TXA and PAI of TXA, and group 4 (n = 57) received double placebo (IAI of placebo and PAI of placebo). The demographic characteristics, surgical indices, hematological indices, wound healing history, and thromboembolic events were investigated. RESULTS: Eight patients were lost to follow-up and 210 patients were included in the analysis. The median TBLs in patients who received IAI of TXA and PAI of placebo and those who received IAI of placebo and PAI of TXA were 470.81 ml and 481.54 ml, respectively. These TBL levels were significantly higher compared to those in patients who received IAI of TXA and PAI of TXA (359.18 ml, P ≤ .001), but significantly lower compared to those in patients who received the double placebo (522.71 ml, P ≤ .001). Compared to other groups, more patients in the double placebo group needed a blood transfusion (P = .013). In the short-term, the double placebo group had higher VAS pain scores and less ROM after surgery (P = .011 and P = .001, respectively). In the long-term (6-month follow-up), there were no significant differences in ROM, VAS, DVT, PE, or wound-related complications. CONCLUSION: The combined use of IAI and PAI of TXA can significantly reduce the TBL and the need for blood transfusion without delaying wound healing or increasing the risk of DVT and PE. In the short-term after surgery, this combined method reduces the pain VAS scores and improves the ROM; however, there are no long-term effects on VAS and ROM.
format Online
Article
Text
id pubmed-6709093
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67090932019-10-01 Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial Zhang, Shenqi Wang, Chengbin Shi, Lei Xue, Qingyun Medicine (Baltimore) Research Article BACKGROUND: Perioperative bleeding during total knee arthroplasty (TKA) is an ongoing problem for surgeons. Intravenous or topical application of tranexamic acid (TXA) can effectively stop bleeding, but there is still no uniform standard for the best method of administration and dose. METHODS: From October 2016 to September 2018, 218 patients with unilateral primary knee osteoarthritis requiring knee replacement were enrolled and randomly divided into four groups. Group 1 (n = 55) received intra-articular injection (IAI) of TXA and peri-articular injection (PAI) of placebo, group 2 (n = 55) received IAI of placebo and PAI of TXA, group 3 (n = 51) received IAI of TXA and PAI of TXA, and group 4 (n = 57) received double placebo (IAI of placebo and PAI of placebo). The demographic characteristics, surgical indices, hematological indices, wound healing history, and thromboembolic events were investigated. RESULTS: Eight patients were lost to follow-up and 210 patients were included in the analysis. The median TBLs in patients who received IAI of TXA and PAI of placebo and those who received IAI of placebo and PAI of TXA were 470.81 ml and 481.54 ml, respectively. These TBL levels were significantly higher compared to those in patients who received IAI of TXA and PAI of TXA (359.18 ml, P ≤ .001), but significantly lower compared to those in patients who received the double placebo (522.71 ml, P ≤ .001). Compared to other groups, more patients in the double placebo group needed a blood transfusion (P = .013). In the short-term, the double placebo group had higher VAS pain scores and less ROM after surgery (P = .011 and P = .001, respectively). In the long-term (6-month follow-up), there were no significant differences in ROM, VAS, DVT, PE, or wound-related complications. CONCLUSION: The combined use of IAI and PAI of TXA can significantly reduce the TBL and the need for blood transfusion without delaying wound healing or increasing the risk of DVT and PE. In the short-term after surgery, this combined method reduces the pain VAS scores and improves the ROM; however, there are no long-term effects on VAS and ROM. Wolters Kluwer Health 2019-07-26 /pmc/articles/PMC6709093/ /pubmed/31348286 http://dx.doi.org/10.1097/MD.0000000000016570 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Zhang, Shenqi
Wang, Chengbin
Shi, Lei
Xue, Qingyun
Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial
title Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial
title_full Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial
title_fullStr Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial
title_full_unstemmed Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial
title_short Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial
title_sort multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709093/
https://www.ncbi.nlm.nih.gov/pubmed/31348286
http://dx.doi.org/10.1097/MD.0000000000016570
work_keys_str_mv AT zhangshenqi multirouteapplicationsoftranexamicacidtoreducebloodlossaftertotalkneearthroplastyarandomizedcontrolledtrial
AT wangchengbin multirouteapplicationsoftranexamicacidtoreducebloodlossaftertotalkneearthroplastyarandomizedcontrolledtrial
AT shilei multirouteapplicationsoftranexamicacidtoreducebloodlossaftertotalkneearthroplastyarandomizedcontrolledtrial
AT xueqingyun multirouteapplicationsoftranexamicacidtoreducebloodlossaftertotalkneearthroplastyarandomizedcontrolledtrial